Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
7,819,192
-
Total 13F shares
-
3,389,769
-
Share change
-
-1,592,455
-
Total reported value
-
$9,926,381
-
Put/Call ratio
-
125%
-
Price per share
-
$2.93
-
Number of holders
-
25
-
Value change
-
-$3,961,051
-
Number of buys
-
15
-
Number of sells
-
9
Institutional Holders of PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) as of Q4 2022
As of 31 Dec 2022,
PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) was held by
25 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,389,769 shares.
The largest 10 holders included
Ayrton Capital LLC, K2 PRINCIPAL FUND, L.P., VANGUARD GROUP INC, EQUITEC PROPRIETARY MARKETS, LLC, GEODE CAPITAL MANAGEMENT, LLC, SABBY MANAGEMENT, LLC, SIMPLEX TRADING, LLC, STATE STREET CORP, IQ EQ FUND MANAGEMENT (IRELAND) Ltd, and NORTHERN TRUST CORP.
This page lists
25
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.